Meeting News

Top pulmonology news from October: ERS International Congress coverage, effects of e-cigarettes and more

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in October.

See below for links to studies on new treatments for interstitial lung disease presented at the European Respiratory Society International Congress, FDA approvals and rejections, updates on the outbreak of electronic cigarette-related lung injuries and more.

Triple therapy approved to treat cystic fibrosis

The FDA announced it has approved elexacaftor/ivacaftor/tezacaftor, the first triple combination therapy for patients with the most common cystic fibrosis mutation. Read more

CDC provides update on vaping-related injuries

As of Oct. 8, 1,299 confirmed and probable cases of lung injury associated with electronic cigarette use, or vaping, have been reported by 49 states, the District of Columbia and the U.S. Virgin Islands. There have also been 26 deaths confirmed and reported to CDC from 21 states, including a death in a patient aged only 17 years, Anne Schuchat, MD, CDC principal deputy director, said during a telebriefing.

Read more

E-cigarette flavor may affect asthma pathophysiology

The effect of electronic cigarettes without nicotine on allergic airway disease may depend on flavor, which suggests that some flavored e-cigarettes may alter the pathophysiology of asthma, a recent study on mice suggests. Read more

Occupational exposure to disinfectants may raise COPD risk

New data published in JAMA Network Open showed that the risk for COPD incidence was higher among nurses who regularly performed cleaning and disinfectant tasks. Read more

Stone fabrication workers at risk for silicosis

Eighteen cases of silicosis in stone fabrication workers have highlighted the occupational risk faced by those who work with engineered stone, according to findings published in Morbidity and Mortality Weekly Report. Read more

Triple therapy fails to win FDA approval for COPD

The FDA has issued a complete response letter regarding the new drug application for PT010 — an inhaled triple-combination therapy — for COPD, according to a press release from the manufacturer. Read more

INBUILD: Nintedanib slows progression of fibrosing ILD

When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress. Read more

Pamrevlumab may be safe, effective in IPF

In a phase 2 trial, pamrevlumab, a fully recombinant human monoclonal antibody against connective tissue growth factor, appeared to reduce the decline in lung function among patients with idiopathic pulmonary fibrosis. Read more

Pirfenidone promising for unclassifiable ILD

Pirfenidone treatment was associated with improvement in several outcomes among patients with progressive fibrosing unclassifiable interstitial lung disease, according to a new study. Read more

Three-in-one asthma inhaler may improve lung function, reduce exacerbations

The addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting beta-2 agonist therapy in a single inhaler improves lung function and reduces exacerbations among patients with uncontrolled asthma, according to data from two phase 3 studies presented at the European Respiratory Society International Congress. Read more

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in October.

See below for links to studies on new treatments for interstitial lung disease presented at the European Respiratory Society International Congress, FDA approvals and rejections, updates on the outbreak of electronic cigarette-related lung injuries and more.

Triple therapy approved to treat cystic fibrosis

The FDA announced it has approved elexacaftor/ivacaftor/tezacaftor, the first triple combination therapy for patients with the most common cystic fibrosis mutation. Read more

CDC provides update on vaping-related injuries

As of Oct. 8, 1,299 confirmed and probable cases of lung injury associated with electronic cigarette use, or vaping, have been reported by 49 states, the District of Columbia and the U.S. Virgin Islands. There have also been 26 deaths confirmed and reported to CDC from 21 states, including a death in a patient aged only 17 years, Anne Schuchat, MD, CDC principal deputy director, said during a telebriefing.

Read more

E-cigarette flavor may affect asthma pathophysiology

The effect of electronic cigarettes without nicotine on allergic airway disease may depend on flavor, which suggests that some flavored e-cigarettes may alter the pathophysiology of asthma, a recent study on mice suggests. Read more

Occupational exposure to disinfectants may raise COPD risk

New data published in JAMA Network Open showed that the risk for COPD incidence was higher among nurses who regularly performed cleaning and disinfectant tasks. Read more

Stone fabrication workers at risk for silicosis

Eighteen cases of silicosis in stone fabrication workers have highlighted the occupational risk faced by those who work with engineered stone, according to findings published in Morbidity and Mortality Weekly Report. Read more

Triple therapy fails to win FDA approval for COPD

The FDA has issued a complete response letter regarding the new drug application for PT010 — an inhaled triple-combination therapy — for COPD, according to a press release from the manufacturer. Read more

INBUILD: Nintedanib slows progression of fibrosing ILD

When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress. Read more

PAGE BREAK

Pamrevlumab may be safe, effective in IPF

In a phase 2 trial, pamrevlumab, a fully recombinant human monoclonal antibody against connective tissue growth factor, appeared to reduce the decline in lung function among patients with idiopathic pulmonary fibrosis. Read more

Pirfenidone promising for unclassifiable ILD

Pirfenidone treatment was associated with improvement in several outcomes among patients with progressive fibrosing unclassifiable interstitial lung disease, according to a new study. Read more

Three-in-one asthma inhaler may improve lung function, reduce exacerbations

The addition of a long-acting muscarinic antagonist to inhaled corticosteroid plus long-acting beta-2 agonist therapy in a single inhaler improves lung function and reduces exacerbations among patients with uncontrolled asthma, according to data from two phase 3 studies presented at the European Respiratory Society International Congress. Read more